Although the clinical use of anti‐CTLA‐4 antibody and anti‐PD‐1/PD‐L1 antibody is considered to be a revolution in cancer therapy, most patients eventually relapse due to drug resistance; therefore, it is an urgent problem to discover new treatment schemes. The gene discussed is CTLA4; the disease is cancer.